local_hospital

Ioannou Private Clinic-Private Polyclinics S.A.

Address
Vernardaki 13 Str, 383 33 Volos, Greece

Ioannou Private Clinic-Private Polyclinics S.A.

Ioannou Private Clinic-Private Polyclinics S.A. is a distinguished clinical research facility specializing in advanced oncology trials, with particular emphasis on urological malignancies and lung cancer therapeutics. The center demonstrates significant expertise in evaluating novel treatment modalities and biosimilar agents for patients with advanced and metastatic cancers.

  • Urothelial cancer research, including locally advanced and metastatic disease, and muscle-invasive bladder cancer (MIBC)
  • Innovative antibody-drug conjugate therapies and targeted intravesical delivery systems
  • Non-small cell lung cancer (NSCLC) studies, including biosimilar evaluation and immunotherapy development

The facility conducts comprehensive Phase II and comparative efficacy trials, utilizing blinded independent central review (BICR) methodologies and RECIST 1.1 criteria for precise response evaluation. Their research portfolio encompasses combination immunotherapy regimens, chemoradiotherapy comparisons, and pharmacokinetic assessments, positioning them at the forefront of evaluating both breakthrough therapies and biosimilar alternatives for oncology patients.

Site Overview

assignment
3
connected trials
corporate_fare
3
sponsors
science
11
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
3
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
2
Sponsors (total)
3
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 173 other sites in Greece

description
Trial volume
3
Outperforms 51% of sites
public
Therapeutic diversity
1areas
Outperforms 2% of sites
groups
Sponsor diversity
3sponsors
Outperforms 56% of sites

Therapeutic Area Benchmark — Greece

Select a therapeutic area to compare against other sites in Greece.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Greece

Market Share

Country: Greece

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Ioannou Private Clinic-Private Polyclinics S.A.

lock Showing 1 of 3 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Comparative Study of Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 and Pembrolizumab in Advanced/Metastatic Non-Squamous NSCLCMabxience Research S.L.Phase IIIRecruitingSep 2025

IMP list

lock Showing 1 of 11 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Cisplatin2Unknown2019-05-072021-04-20

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.